NCT00082628已完成3 期
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- EMD Serono
- 入组人数
- 326
- 试验地点
- 31
- 主要终点
- Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12
研究概览
简要总结
The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT, measured by CT scan) more effectively than placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have written laboratory documentation of an HIV infection by one of the following methods:
- •Detectable viral load measured by polymerase chain reaction (PCR) amplification, branched chain DNA (bDNA) signal amplification or the presence of p24 antigen.
- •Presence of HIV antibodies confirmed by either Western blot or immunofluorescence assay.
- •Written laboratory documentation of an HIV infection must be obtained prior to randomization. In the absence of documented historical confirmation, an assay of HIV antibodies will be included in the Screening Laboratory Panel. Results will be confirmed with a Western Blot.
- •Have evidence of excess abdominal adipose deposition when measured by the anthropometric methodology, using the following cut off values:
- •Men: Waist circumference >88.2 cm AND waist: hip ratio >= 0.
- •Women: Waist circumference >75.3 cm AND waist: hip ratio >= 0.
- •Are taking antiretroviral medication(s) which is (are) approved or is (are) available under a Treatment IND. The regimen must have remained stable for 30 days prior to study entry. Subjects must also agree not to discontinue or to change their regimen for the duration of the study except as judged medically necessary.
- •Have parameter values less than the following limits (using results from the central laboratory):
- •AST, ALT, and amylase <= 3 times the upper limit of normal (Screening).
- •Fasting triglycerides <= 1,000 mg/dL (Screening).
- •Fasting glucose <110 mg/dL (Screening).
- •Two-hour (120 minute) glucose <140 mg/dL (Screening).
- •Weight >= 36 kg (79.3 lb)
- •Be between 18 and 60 years of age (inclusive) unless local law dictates different limits.
- •Sufficiently literate in English to be able to comprehend and complete the Quality of Life Questionnaire.
- •Willing and able to comply with the protocol for the duration of the study.
- •Have voluntarily provided written informed consent (with subject authorization under HIPAA), prior to performing any study-related procedure that is not part of normal medical care, and with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
- •Female subjects must:
- •Be post menopausal (>= 1 year) or surgically sterilized (i.e., have undergone tubal ligation or hysterectomy)
- •Use a contraceptive method for the duration of the study such as:
- •Hormonal contraceptive
- •Intra uterine device
- •Diaphragm with spermicide, or condom with spermicide.
- •Must be neither pregnant nor breast feeding.
- •Confirmation that female subjects of childbearing potential are not pregnant must be established by a negative beta-hCG serum pregnancy test during the 14-day screening period prior to Study Day
- •If the beta-hCG serum pregnancy test is performed more than 7 days prior to Study Day 1, a urine pregnancy test must be performed by the site laboratory on Study Day 1 to confirm a negative test result.
排除标准
- •Have an active AIDS-defining opportunistic complication (OC) as defined by the CDC or have had an untreated or suspected serious systemic infection, or have had a persistent fever >= 101°F (38.3°C) during the 30 days prior to study entry.
- •Any active or past history of malignancy, except for localized cutaneous Kaposi's sarcoma (fewer than 10 lesions, none of which are larger than 2 cm, and not on active therapy). Such exceptions must be confirmed in writing by the Serono Study Director.
- •Have a CNS mass or active CNS process associated with neurological findings.
- •Have unstable or untreated hypertension, defined as >= 140/90 mm Hg at the time of the Screening Visit, and/or have initiated or changed antihypertensive therapy in the 30 days prior to Study Day
- •Have an acute critical illness treated in an intensive care unit, e.g., due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure.
- •Have a recent history of sleep apnea or intermittent upper respiratory obstruction.
- •Have any condition, which interferes with informed consent or protocol compliance including, but not limited to, active substance abuse and/or dementia.
- •Are unable to comply with the Concomitant Therapy restrictions including:
- •therapy for obesity including therapy with anorexigenic or fat reducing drugs
- •anti-diabetic or insulin sensitizing medications
- •systemic glucocorticoids
- •systemic chemotherapy, interferon or radiation therapy treatment
- •androgenic agents including, but not limited to testosterone, nandrolone, oxandrolone, oxymetholone, etc. (testosterone replacement therapy for hypogonadism is the exception to this exclusion and will be allowed if started > 30 days prior to Study Day 1)
- •progestational agents, unless used for oral contraception or post-menopausal hormone replacement therapy
- •appetite stimulants
- •investigational agents, unless approved in advance by the study medical director. Specifically, experimental antiretroviral agents are disallowed, unless available under a treatment IND or expanded access program (30 days).
- •Liposuction or other elective plastic surgery
- •AIDS wasting therapy or prior growth hormone treatment other than study drug (for 12 months prior to the screening visit)
- •Have ever been diagnosed with any of the following conditions:
- •Pancreatitis
- •Carpal tunnel syndrome (unless resolved by surgical release)
- •Diabetes mellitus
- •Angina pectoris
- •Coronary artery disease
- •Any disorder associated with moderate to severe edema (e.g., ascites, nephrotic syndrome, congestive heart failure, lymphedema).
- •Allergy or hypersensitivity to growth hormone.
- •Are participating in any other clinical studies.
- •In order to participate in this trial a subject must meet all of the inclusion and exclusion criteria specified above. Requests for protocol exceptions/exemptions must come from a participating, fully initiated site at which a prospective patient has consented to undergo screening. Exceptions/exemptions are only allowed by the Trial Director. There is no program in place to allow drug for a single patient IND, or for an expanded access protocol. This statement holds true for both children and adults.
研究组 & 干预措施
Period I: Placebo
Placebo Comparator
Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.
干预措施: Placebo (Drug)
Period I: Serostim® 4 mg
Experimental
Subjects will receive Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.
干预措施: Serostim® 4 mg (Drug)
Period II: Serostim® 4 mg to Placebo
Experimental
All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive placebo matched to Serostim® on alternate days for 24 weeks in Period II.
干预措施: Placebo (Drug)
Period II: Serostim® 4 mg to Serostim® 2 mg
Experimental
All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive Serostim® 2 mg on alternate days for 24 weeks in Period II.
干预措施: Serostim® 2 mg (Drug)
Period II: Placebo to Placebo/Serostim® 4 mg
Experimental
All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.
干预措施: Placebo (Drug)
Period II: Placebo to Placebo/Serostim® 4 mg
Experimental
All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.
干预措施: Serostim® 4 mg (Drug)
结局指标
主要结局
Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12
时间窗: Baseline, Week 12
Absolute area of VAT was measured by cross-sectional computed tomography (CT) scan at the level of the L4-5 inter-vertebral disk. CT scanning was to be used to assess the cross sectional area of abdominal fat and its distribution between the visceral and subcutaneous compartments, as measured at L4-L5.
次要结局
- Treatment Period I: Change From Baseline in Trunk Fat at Week 12(Baseline, Week 12)
- Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12(Baseline, Week 12)
- Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12(Baseline, Week 12)
- Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I(Week 36)
研究者
研究点 (31)
Loading locations...
相似试验
已完成
3 期
Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery LesionsCoronary Artery DiseaseNCT00232752Cordis Corporation100
已完成
2 期
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisPsoriasisNCT00678210Pfizer197
已完成
3 期
A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)NCT06103825Ignis Therapeutics (Suzhou) Limited204
已完成
4 期
Stroke Treatment With Acute Reperfusion and SimvastatinStroke, AcuteNCT01073007Hospital Universitari Vall d'Hebron Research Institute104
已完成
3 期
Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)Coronary Artery DiseaseNCT00232765Cordis Corporation1,058